Network-1 Technologies, Inc. Reports 2025 Year-End Financial Results
Network-1 Technologies, Inc. Reports 2025 Year-End Financial Results
Key Highlights
- Net Loss Narrows: Network-1 reported a net loss of \$2.42 million (\$0.11 per share) for the year ended December 31, 2025, compared to a net loss of \$3.03 million (\$0.13 per share) for 2024.
- Revenue Increase: Total revenue for 2025 was \$150,000, up from \$100,000 in 2024.
- Stable Dividend: The company declared a cash dividend of \$0.10 per share, unchanged from the prior year.
- Interest and Dividend Income: Interest and dividend income totaled \$1.84 million in 2025, slightly down from \$1.90 million in 2024.
- Gains on Securities: Realized and unrealized gains on marketable securities were \$277,000 in 2025, compared to \$177,000 in 2024.
- Equity Method Investment Loss: Included in the net loss is Network-1’s share of the net loss of its equity method investee, ILiAD Biotechnologies, of \$1.60 million in 2025, down from \$1.91 million in 2024.
- Strong Cash and Marketable Securities Position: As of December 31, 2025, the company reported marketable securities at fair value of \$23.47 million, compared to \$27.46 million at year-end 2024, and total assets of \$40.33 million (down from \$45.41 million in 2024).
- Stockholders’ Equity: Stockholders’ equity stood at \$44.31 million as of December 31, 2025.
Detailed Financial Overview
| Item |
2025 |
2024 |
| Revenue |
\$150,000 |
\$100,000 |
| Operating Loss |
(\$3,306,000) |
(\$3,621,000) |
| Interest and Dividend Income |
\$1,844,000 |
\$1,897,000 |
| Net Realized & Unrealized Gains on Securities |
\$277,000 |
\$177,000 |
| Net Loss |
(\$2,420,000) |
(\$3,034,000) |
| Net Loss Per Share (Basic) |
(\$0.11) |
(\$0.13) |
| Weighted Avg. Shares Outstanding |
23,250,224 |
Not stated |
| Cash Dividends Declared Per Share |
\$0.10 |
\$0.10 |
| Total Assets |
\$40,332,000 |
\$45,414,000 |
| Marketable Securities (Fair Value) |
\$23,467,000 |
\$27,455,000 |
| Stockholders’ Equity |
\$44,311,000 |
Not stated |
Important Information for Shareholders
- Improvement in Net Loss: The reduction in net loss year-over-year is a positive sign, reflecting improved cost management and higher investment gains. This could bolster investor confidence, though the company remains in a loss position.
- Stable Dividend: The maintenance of the \$0.10 per share dividend is noteworthy, especially given the ongoing net losses, and signals management’s commitment to returning value to shareholders.
- Decreased Marketable Securities: The decline in marketable securities and total assets may be a concern if the trend continues, as it could restrict the company’s financial flexibility.
- Ongoing Losses from Equity Investment: The continued losses from ILiAD Biotechnologies are material and should be monitored by shareholders, as persistent losses from this investment could have a further negative impact on Network-1’s results.
- Risk of Personal Holding Company Status: The company stated there is a risk in the future of being classified as a Personal Holding Company, which may result in Network-1 issuing a special cash dividend to its stockholders. This could have tax and valuation implications for shareholders.
- Strategic Initiatives and Outlook: The ability to enter into strategic relationships and monetize intellectual property remains a key factor for future performance. The company cautions about potential regulatory, competitive, and economic changes.
Corporate Overview
Network-1 Technologies, Inc. (NYSE American: NTIP) is focused on the acquisition, development, licensing, and monetization of intellectual property assets. The company’s revenue streams are still modest, and it relies largely on investment income and gains from securities to offset operating expenses and losses from its strategic investments.
Contacts
Network-1 Technologies, Inc.
Corey M. Horowitz, Chairman and CEO
(917) 692-0000
Price-Sensitive or Shareholder-Relevant Issues
- A smaller net loss and stable dividend may support the share price in the short term.
- Ongoing losses from investments and declining asset base could pressure the valuation if not reversed.
- Any announcement related to monetization of intellectual property, or developments at ILiAD Biotechnologies, could be significant for the share price.
- Potential classification as a Personal Holding Company and the possible issuance of a special cash dividend are notable and could affect shareholder returns and tax positions.
Disclaimer: This article is a summary and analysis based on company-provided filings and is intended for informational purposes only. It does not constitute investment advice. Readers should consult their own financial advisors before making any investment decisions. The company’s results are subject to change, and forward-looking statements may not materialize as described.
View NETWORK-1 TECHNOLOGIES, INC. Historical chart here
